Canada markets closed


Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.0000-0.0100 (-0.50%)
At close: 3:19PM EST
Sign in to post a message.
  • P
    This is going parabolic when people will see the potential of this stock
  • A
    Is there any big news coming. Someone suddenly bought a big chunk.
    Good news...
  • P
    This is all fine and great but when do we get at least emergency authorizations so the stock can move
  • T
    IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
  • A
  • A
    Is it abandoned ? No News, No movement? ... Frustrating ...
  • P
    We need some news and update on clinicals They didnt even mention covid vacine on their earnings call. Management we need updates now
  • A
    Have everyone abandoned this stock !!!........ So Quite ...No movement...
  • r
    Nothing from mgmt never a good signal ... Going lower ...
  • A
    What's happening to this? No movement !!!
  • W
    Good News!!
    IMV today announced that Canadian government agencies will contribute up to
    CA$4.75 mln to advance Phase 1 clinical development of its vaccine candidate,
    DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel
    coronavirus SARS-COV-2.
    The company is receiving CA$4.15 mln advisory services and funding from the
    National Research Council of Canada Industrial Research Assistance Program,
    Atlantic Canada Opportunities Agency, and Next Generation Manufacturing Canada to
    support rapid scale-up of DPX-COVID-19 manufacturing process and its evaluation in
    a phase 1 clinical trial. In addition to this funding, IMV also received CA$600,000 from
    the NRC IRAP Innovation Assistance Program.
    IMV plans to use funding from to advance DPX-COVID-19 with a Phase I clinical trial
    starting this summer in Canada. A Phase 2 trial is expected to start by end of 2020 in
    the US and Canada following successful Phase 1 top-line results that are expected
    later this year. Funding will also support the cale-up manufacturing capacity for
    commercial production for North American and global markets.
  • M
    DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at BTIG’s Virtual Biotechnology Conference on Monday August 10, 2020 at 11 a.m. EDT.
    A live webcast of this presentation will be available under “Events, Webcasts and Presentations” in the investors section of the IMV website and a replay will be available approximately one hour after the presentation. Afterwards, it will be available for approximately 30 days.
    About IMV
    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19. Visit and connect with us on Twitter and LinkedIn.
    IMV Inc. is a clinical-stage biopharmaceutical company developing a new class of cancer immunotherapies and vaccines against infectious diseases
    IMV Inc. is a clinical-stage biopharmaceutical company developing a new class of cancer immunotherapies and vaccines against infectious diseases
  • r
    Found this in one of the blog sites:

    "I spoke to the company and they are convinced they will get Breakthrough Therapy designation from the FDA. The biomarker data is so strong, this will propell the stock into 2021!

    Drugs that have been granted breakthrough status are given priority review. The FDA works with the sponsor of the drug application to expedite the approval process. This expedited process can include rolling reviews, smaller clinical trials, and alternative trial designs.[9]"
  • Y
    Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19

    Clinical plan updated to run a larger Phase 1/2 study with the goal to expedite later-stage development

    Collaboration initiated with a global manufacturing partner to develop and expand manufacturing capacity up to several hundred million of doses.
    IMV Provides Updates On COVID-19 Vaccine Program
  • A
    Offers in IMV are said to be spiking approx. 134% in Tuesday's pre-advertise exchanging after the clinical-stage biopharma organization said it made "fast advancement" in building up its up-and-comer antibody to forestall COVID-19 disease. Read more here:
    UnderValued Hidden Company Is Expanding Quickly Into A Multi Billion Dollar Market. 4/20 Investor
  • T
    The key difference between IMV vs RMNA is: We believe our vaccine candidate would retain its potential efficacy independently from current/future mutations of the virus at this site! With RMNA, they need to modify and update the vaccine as virus mutates but with IMV, not necessary! This is huge!
  • T
    On September 30, 2020, the Company had cash and cash equivalents of $54,700,000 and working capital of $55,875,000, compared with $14,066,000 and $13,199,000, respectively at December 31, 2019
  • P
    They better give a timeline thursday as to when the hell all of this moves to final approval or at least phase 3
  • M
    Are we ready for this week guys?? I will not sell on Monday although I already have %100 profits, this will go much higher. Partnerships with Merck for cancer drugs, Phase 2 studies results soon, no more stock offerings in short term, wells' great PT, very low RSI. See you guys at $10+
  • J
    Monday December 7th 2020,

    PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of
    86 % associated with long duration of clinical benefits.

    IMV Inc. (Nasdaq:IMV; TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that durable clinical benefits induced by combination treatment of IMV’s T cell therapy with Merck’s Keytruda® (pembrolizumab) in subjects with PD-L1 positive recurrent/refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) have been presented at the American Society of Hematology (ASH) Annual Meeting.